Obesity medications may prevent further damage after a heart attack

The Unexpected Role of Obesity Treatments

Can a drug designed to promote weight loss protect the heart muscle after a heart attack? This idea may seem surprising, yet recent scientific research has yielded compelling results. GLP-1 receptor agonists, commonly prescribed for diabetes and obesity, offer new avenues for optimizing heart recovery.

Researchers from the University of Bristol and University College London have examined this question. Their work demonstrates that these specific molecules have the ability to improve cardiac recovery following a cardiovascular event.

When a heart attack occurs, a blood vessel supplying the heart becomes blocked. This vital organ requires a constant supply of oxygen-rich blood to function optimally. As soon as this flow is interrupted, part of the heart muscle begins to suffer severe damage.

The Invisible Phenomenon of No-Reflow

Faced with this life-threatening emergency, medical teams act quickly to unblock the main artery. This first-line procedure saves many lives every day. However, even after this successful reopening, full recovery of the heart muscle is not always guaranteed.

A major obstacle, often overlooked by the general public, complicates the healing process. Nearly half of patients who suffer a heart attack experience a phenomenon known as no-reflow, which results in the persistent blockage of microscopic blood vessels within the heart. Although the main artery is cleared, blood is unable to reach certain areas of the heart muscle.

This blockage is caused by the action of very small cells, called pericytes, which constrict around the microvessels. This constriction prevents the smooth flow of blood, depriving the heart of the oxygen it needs. Such a situation significantly increases the risk of developing heart failure or experiencing serious complications within the year following the heart attack.

Surprising discoveries by research teams

Understanding this restrictive mechanism has been the subject of numerous clinical observations. Dr. Svetlana Mastitskaya, the lead author of this new study, sheds crucial light on the impact of pericytes on the long-term health of recovering patients.

She explains this phenomenon in detail: “Our previous research has shown that this narrowing of blood vessels contributes significantly to ‘no-reflow,’ a complication that increases the risk of death or hospitalization for heart failure within a year of a heart attack,”

The researcher emphasizes the promise of potential solutions emerging today: “But our latest findings are surprising in that we’ve discovered that GLP-1 medications might prevent this problem.”

The mechanism of blood flow restoration

GLP-1 is naturally produced in the intestine. The medical community already uses drugs that mimic this hormone to treat type 2 diabetes and obesity. These substances help regulate blood sugar levels while reducing patients’ appetite. Previous studies had also noted that people on this treatment experienced fewer serious heart problems, prompting scientists to investigate the exact cause.

To test their hypothesis, the researchers conducted experiments on animal models. After inducing and then treating a heart attack, they found that numerous microvessels remained blocked in the untreated hearts. Upon administering a GLP-1 drug, a large portion of these small channels reopened, thereby reducing heart damage through restored blood flow.

The study explains that the drug works by activating tiny channels inside cells that control how much blood vessels constrict or relax. Under the effect of the treatment, the pericytes relax, the small vessels widen, and blood flows freely to deliver the oxygen essential for healing heart tissue.

A New Lease on Life for Existing Treatments

This scientific breakthrough is generating significant interest because it builds on treatments already widely available in pharmacies. Clinicians could use an existing molecule to help patients recover more effectively from a heart attack, bypassing the need to develop entirely new medical formulations from scratch.

Professor David Attwell, a co-author of the study, highlights the scope of these applications: "With a growing number of similar GLP-1 drugs now in clinical use—for conditions ranging from type 2 diabetes and obesity to kidney disease—our findings highlight the potential for these existing drugs to be repurposed to treat the risk of ‘no-reflow’ in patients who have suffered a heart attack, offering a potentially life-saving solution,"

This research, the full results of which are published in the scientific journal Nature Communications, underscores a fundamental fact of human physiology. Treating the heart is not limited to unblocking its large blood vessels. The smallest vessels play an equally vital role in giving the muscle a real chance at recovery and ongoing strengthening.

According to the source: earth.com

Obesity medications may prevent further damage after a heart attack